scholarly journals Discovery of Nosiheptide, Griseoviridin, and Etamycin as Potent Anti-Mycobacterial Agents against Mycobacterium avium Complex

Molecules ◽  
2019 ◽  
Vol 24 (8) ◽  
pp. 1495
Author(s):  
Hosoda ◽  
Koyama ◽  
Kanamoto ◽  
Tomoda
Keyword(s):  
Therapeutic Effect ◽  
Mycobacterium Avium ◽  
Mycobacterium Avium Complex ◽  
Culture Broth ◽  
Therapeutic Effects ◽  
Strong Activity ◽  
Minimum Inhibitory Concentrations ◽  
Marine Actinomycete ◽  
Serious Disease ◽  
Microbial Samples

Mycobacterium avium complex (MAC) is a serious disease mainly caused by M. avium and M. intracellulare. Although the incidence of MAC infection is increasing worldwide, only a few agents are clinically used, and their therapeutic effects are limited. Therefore, new anti-MAC agents are needed. Approximately 6600 microbial samples were screened for new anti-mycobacterial agents that inhibit the growth of both M. avium and M. intracellulare, and two culture broths derived from marine actinomycete strains OPMA1245 and OPMA1730 had strong activity. Nosiheptide (1) was isolated from the culture broth of OPMA1245, and griseoviridin (2) and etamycin (viridogrisein) (3) were isolated from the culture broth of OPMA1730. They had potent anti-mycobacterial activity against M. avium and M. intracellulare with minimum inhibitory concentrations (MICs) between 0.024 and 1.56 μg/mL. In addition, a combination of 2 and 3 markedly enhanced the anti-mycobacterial activity against both M. avium and M. intracellulare. Furthermore, a combination 2 and 3 had a therapeutic effect comparable to that of ethambutol in a silkworm infection assay with M. smegmatis.

scholarly journals Comparative In Vitro Antimicrobial Activities of the Newly Synthesized Quinolone HSR-903, Sitafloxacin (DU-6859a), Gatifloxacin (AM-1155), and Levofloxacin againstMycobacterium tuberculosis and Mycobacterium avium Complex

1999 ◽  
Vol 43 (12) ◽  
pp. 3001-3004 ◽  
Author(s):  
Haruaki Tomioka ◽  
Katsumasa Sato ◽  
Tatsuya Akaki ◽  
Hiroko Kajitani ◽  
Shin Kawahara ◽  
...  
Keyword(s):  
Mycobacterium Avium ◽  
Mycobacterium Avium Complex ◽  
Antimycobacterial Activity ◽  
Antimicrobial Activities ◽  
Type Ii ◽  
Alveolar Cells ◽  
Strong Activity ◽  
Type Ii Alveolar Cells ◽  
Gram Positive Cocci

ABSTRACT We compared the in vitro antimycobacterial activity of a new fluoroquinolone, HSR-903, with strong activity against gram-positive cocci with those of levofloxacin (LVFX), sitafloxacin (STFX), and gatifloxacin (GFLX). The MICs of the quinolones for Mycobacterium tuberculosis and Mycobacterium avium complex were in the order STFX ≈ GFLX < LVFX ≦ HSR-903 and STFX ≦ GFLX ≦ HSR-903 ≦ LVFX, respectively. HSR-903 effectively eliminated intramacrophagial M. tuberculosis, as did LVFX, and exhibited bacteriostatic effects against M. tuberculosis replicating in type II alveolar cells.

Therapeutic Effects of Various Initial Combinations of Chemotherapy Including Clarithromycin Against Mycobacterium avium Complex Pulmonary Disease

CHEST Journal ◽  
2009 ◽  
Vol 136 (6) ◽  
pp. 1569-1575 ◽  
Author(s):  
Naoki Hasegawa ◽  
Tomoyasu Nishimura ◽  
Sumire Ohtani ◽  
Kei Takeshita ◽  
Koichi Fukunaga ◽  
...  
Keyword(s):  
Pulmonary Disease ◽  
Mycobacterium Avium ◽  
Mycobacterium Avium Complex ◽  
Therapeutic Effects

Polymicrobial Intracerebral Abscess Growing Achromobacter Xylosoxidans and Mycobacterium Avium Complex

2020 ◽  
Author(s):  
Juliana Rotter ◽  
Christopher S. Graffeo ◽  
Hannah E. Gilder ◽  
Lucas P. Carlstrom ◽  
Avital Perry ◽  
...  
Keyword(s):  
Mycobacterium Avium ◽  
Mycobacterium Avium Complex ◽  
Achromobacter Xylosoxidans ◽  
Intracerebral Abscess
Sign in / Sign up

Export Citation Format

Share Document